# Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

> **NCT05182034** · PHASE2 · COMPLETED · sponsor: **Medipost Co Ltd.** · enrollment: 94 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **BIOLOGICAL:** SMUP-IA-01(low dose)
- **BIOLOGICAL:** SMUP-IA-01(mid dose)
- **DRUG:** Active Control Group Sodium chloride

## Key facts

- **NCT ID:** NCT05182034
- **Lead sponsor:** Medipost Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-10-17
- **Final completion:** 2023-10-17
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182034, "Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05182034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*